All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
40 results for "Cancer" and "Endocrine Cancers" and "Other Blood Related"
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
A Phase 1 Study of ADI-001 in B Cell Malignancies
Protocol No
ADICET-ADI-001-BCELL
Sub Category
A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Phase II Study of CART-ddBCMA for the Treatment of Patients with R/R Multiple Myeloma
Protocol No
ARCELLX-ARC-112A-CART-DDBCMA
Sub Category
A Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults
Steroids plus TKI with Blinatumomab or Chemo for Newly Diagnosed BCR-ABL Positive ALL in Adults
Protocol No
ECOG-EA9181-ALL
Sub Category
Phase I Trial of anti-CD20, anti-CD19, anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies
Phase I Trial of CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Protocol No
IIT-SHAH-TRIPLE-CAR20-19-22
Sub Category
Phase I, Open Label Study Of B-Cell Maturation Antigen (BCMA)-Directed CAR-T Cells In Adult Patients With Relapsed And/Or Refractory Multiple Myeloma
BCMA Directed CAR-T Cells in Relapsed And Or Refractory Multiple Myeloma
Protocol No
NOVARTIS-ADPT07A12101BCMA-CART
Sub Category
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Birtamimab plus SOC vs Placebo plus SOC in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Protocol No
PROTHENA-NEOD001-301
Sub Category
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after AlloHCT
Protocol No
DF-HCC-18-265-BOS
Sub Category
GILEAD-5F9009-MDS: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk MDS
Magrolimab + Azacitidine versus Azacitidine + Placebo in Untreated MDS
Protocol No
FORTYSEVEN-5F9009-MDS
Sub Category
A Single-arm, Open-label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 and ALLO-647 to Evaluate an Anti-BMCA Allogeneic CAR T Cell Therapy with or without Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
Phase 1 Study of ALLO-715, an antiBCMA Allo CAR-T cell therapy for pt with rrMM
Protocol No
ALLOGENE-ALLO-715-101-RRMM
Sub Category
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-501A and Anti-CD19 Allogeneic CAR-T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults with rr LBCL
Protocol No
ALLOGENE-ALLO-501A-201
Sub Category
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
To evaluate the safety and tolerability of HMPL-306 in patients with advanced hematological malignancies that harbor IDH mutations and characterize safety and tolerability to determine RP2D of HMPL-306 in patients with advanced hematological malignancies that harbor IDH mutations.
Protocol No
HMP-2020-306-GLOB1
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Ravulizumab in TMA after HSCT
Protocol No
ALEXION-ALXN1210-TMA-313
Sub Category
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category
Master Protocol for the phase 1 Study of Cell therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, including Long-term Safety Follow-up
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Protocol No
ARCELLX-ACLX-001-DDBCMA
Sub Category
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
HLA-Mismatched Unrelated Donor HCT with Post-Transplantation Cyclophosphamide (Access)
Protocol No
NMDP-ACCESS
Sub Category
Open label, multi-center, phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma
Clinical Trial to Evaluate CT053 in Patients with R/R-MM (LUMMICAR Study 2)
Protocol No
CARSGEN-CT053-MM-02
Sub Category
A Phase I Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with r/r MM
Protocol No
FATE-FT576-101-MM
Sub Category
AGAVE-201, A Phase 2, open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patient with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at Least 2 lines of Systemic Therapy.
Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease.
Protocol No
SYNDAX-SNDX-6352-0504-CGVHD
Sub Category
A Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant.
Trial of Viralym-M (ALVR105) for Patients With Virus-Associated Hemorrhagic Cystitis after allo-HCT
Protocol No
ALLOVIR-AVM-003-HC
Sub Category
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Protocol No
HJKC3-0002
Sub Category
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL
Protocol No
IIT-TALANO-CART-ALL
Sub Category